Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02511405
Title A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Acronym GLOBE
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Vascular Biogenics Ltd. operating as VBL Therapeutics
Indications
Therapies
Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.